Benjamin Maxime Morin is a prominent inventor based in Somerville, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of multispecific antibodies. With a total of 6 patents to his name, Morin is recognized for his innovative approaches to therapeutic solutions.

Latest Patents

Morin's latest patents include groundbreaking work on Anti-TIGIT and anti-CD96 antibodies. This patent provides multispecific molecules that specifically bind to CD96 and/or TIGIT, along with isolated antibodies that target human TIGIT. The disclosure also includes pharmaceutical compositions, nucleic acids, expression vectors, and host cells for producing these molecules, as well as methods for treating subjects using these innovations. Another notable patent focuses on Anti-CD73 antibodies, which specifically bind to CD73 and antagonize its function. This patent also includes antibodies that comprise a TGF-β-binding moiety or a VEGF-binding moiety, along with pharmaceutical compositions and methods of treatment.

Career Highlights

Morin is currently associated with Agenus Inc., a company known for its advancements in immunotherapy. His work at Agenus has positioned him as a key player in the development of novel therapeutic antibodies.

Collaborations

Some of Morin's notable coworkers include Nicholas Stuart Wilson and Olga Ignatovich. Their collaborative efforts contribute to the innovative environment at Agenus Inc.

Conclusion

Benjamin Maxime Morin is a distinguished inventor whose work in antibody development has the potential to transform therapeutic approaches in medicine. His contributions continue to pave the way for advancements in biotechnology and immunotherapy.

This text is generated by artificial intelligence and may not be accurate.